# A Dose-Finding Study of MK0974 in Acute Migraine (MK0974-004)

> **NCT00246337** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 420 (actual)

## Conditions studied

- Migraine

## Interventions

- **DRUG:** Comparator: Placebo
- **DRUG:** MK0974
- **DRUG:** MK0974
- **DRUG:** MK0974
- **DRUG:** MK0974
- **DRUG:** MK0974
- **DRUG:** MK0974
- **DRUG:** MK0974
- **DRUG:** Rizatriptan

## Key facts

- **NCT ID:** NCT00246337
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-11
- **Primary completion:** 2006-05
- **Final completion:** 2006-05
- **Target enrollment:** 420 (ACTUAL)
- **Last updated:** 2015-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00246337

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00246337, "A Dose-Finding Study of MK0974 in Acute Migraine (MK0974-004)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00246337. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*